CAI

Caris Life Sciences Stock Analysis

AI Rating

Neutral
  • Quality7/10
  • Growth↑ 7/10
  • Value↓ 1/10
Caris Life Sciences sales and earnings growth
CAI Growth
Good
  • Revenue Y/Y↑ 96.97%
  • EPS Y/Y↑ 69.79%
  • FCF Y/Y↑ 126.37%
Caris Life Sciences gross and profit margin trends
CAI Profitability
Neutral
  • Gross margin ↑ 66.40%
  • EPS margin↓ -66.20%
  • ROIC 5Y↓ 0.00%
Caris Life Sciences net debt vs free cash flow
CAI Risk
Great
  • Debt / Equity↓ 0.7
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -0.2

Caris Life Sciences stock volatility is in-line with the overall market. We give it a Great risk rating.

More Diagnostics & Research stocks ↗